Stem Cell Exosomes for Vitiligo Treatment
Treatments studied
Part of Skin clinical trials.
This study tests whether special particles derived from umbilical cord stem cells can help restore skin color in vitiligo (a condition causing loss of skin pigmentation). The treatment is being tested in adults with vitiligo affecting 1–30% of their body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–65 years old
- Diagnosed with non-segmental vitiligo (the most common type affecting multiple body areas)
- Vitiligo covers 1–30% of your body surface area
- Either stable vitiligo (no changes in past year) or progressive vitiligo (new spots or growth in past 3 months)
- Not pregnant, breastfeeding, or planning to become pregnant
- No other autoimmune diseases or serious heart, liver, or kidney problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a simple blood test to measure immune system signals (cytokines) that may indicate whether vitiligo is active or stable. The goal is to create a model that helps predict how the disease may progress.
This trial tests a new gel made from stem-cell substances (secretome) given with narrow-band UVB light therapy for stable non-segmental vitiligo. It compares two ways of applying the gel to see which works better.
This trial tests whether taking small doses of steroids by mouth for a few days before and after a skin cell transplant (NCES) can reduce the white halo that sometimes forms around the treated area. It is for people with stable vitiligo on the face or trunk that hasn't responded to creams or light therapy.
This trial tests a surgery that uses your own skin cells to treat stable vitiligo patches. It may help when creams or light therapy haven't worked.
This trial tests whether adding short bursts of steroid pills to a skin cell transplant procedure can improve results for people with stable vitiligo on hard-to-treat areas like elbows and knees.
This trial tests whether combining narrowband UVB light with topical steroids can help treat vitiligo, and looks at specific blood markers (CXCL11 and TEMRA) to see how the treatment affects the immune system. It may help patients with stable, non-segmental vitiligo who have not used systemic therapy in the last 3 months.
Hear when a new Vitiligo trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.